Mfn keeps expanding while the benefit for american patients remains unclear
中文标题
mfn不断扩大，但对美国患者的益处仍不明确
Core conclusion · Tlines extraction
The Trump Administration's expansion of most-favored nation (MFN) pricing agreements to 26 pharmaceutical manufacturers is reshaping the global pharma industry by attracting investment into the US while not significantly lowering prices for American patients. The policy will likely accelerate the shift of manufacturing to the US, while Europe faces delays in drug launches and a deteriorating competitive position.
- Institution
- ING THINK
- Published
- 09/03/2026
- Research topic
- Not explicitly stated
- Time horizon
- Not explicitly stated
Key arguments
- MFN pricing has limited direct impact on branded drug prices because it only applies to Medicaid (10% of the market) and new launches, and companies can delay launches in lower-priced markets to manage reference prices.
- The US attracts investment as tariffs and pricing pressures incentivize companies to localize production, with $670 billion in announced industry commitments.
- Europe faces increased access challenges and lagging competitiveness, with drug applications at the European Medicines Agency down 25% year-over-year.
- The root of Europe's decline is institutional fragmentation, not just pricing, requiring comprehensive reforms beyond price increases.
Key numbers
- Number of manufacturers in MFN deals
- 26
- Coverage of branded drug market
- 89%
- US manufacturing investment from nine new signatories
- $19.6bn
- Total industry commitments since tariffs and MFN
- nearly $670bn
- Decline in EU drug applications (first 4 months 2026)
- 25%
- Europe's share of global clinical trials (2009 vs 2024)
- 35% to 20%
Main risks
- Pricing benefits for US patients may be limited, disappointing expectations.
- European patients may face delayed access to new medicines, worsening health outcomes.
- Europe's competitiveness decline could accelerate, leading to loss of investment and innovation.
- The policy may not achieve broad-based price reductions as hoped.
Corresponding source evidence
No sentence-level evidence was extracted; verify the report directly.
Context: the conclusion is Tlines' automated extraction, not the institution's wording. Quoted evidence is publisher wording. Scope and date must travel with the conclusion.
Verify at the original source ↗Loading the document…
AI analysis
How this page was produced
Tlines extracted the conclusion, arguments, numbers and risks above from the report published by ING THINK on 09/03/2026, then structured them for comparison. The publisher's own wording is reachable through the source link on this page and is displayed in full above. Last updated 10/17/2026. Methodology · Source policy · AI usage · Request a correction